Arkolith/Insider Trading/ADMS/Form 4

Mahoney David L

DirectorAdamas Pharmaceuticals Inc (ADMS) · full profile →Form 4 · filed Nov 24, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 24, 2021Tender(U)113K——0
Nov 24, 2021Tender(U)5K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 24, 2021Disposed to issuer(D)10K——0
Nov 24, 2021Disposed to issuer(D)40K——0
Nov 24, 2021Disposed to issuer(D)10K——0
Nov 24, 2021Disposed to issuer(D)10K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001328143-21-000094) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML